<DOC>
	<DOCNO>NCT00392080</DOCNO>
	<brief_summary>CJ-023,423 new medication develop anti-inflammatory agent treatment sign symptom osteoarthritis ( OA ) . The purpose study evaluate whether patient treat CJ-023,423 7 day ( 14 dos ) few gastrointestinal ulcer compare patient treat naproxen placebo .</brief_summary>
	<brief_title>A Study Of The Effect Of CJ-023,423 On The Incidence Of Stomach Ulcers</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Is healthy adult 18 75 year age , inclusive ; healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure [ BP ] pulse rate [ PR ] measurement , 12lead electrocardiogram [ ECG ] , clinical safety laboratory test If female childbearing potential ( include woman postmenopausal &lt; 2 year ) , must use adequate contraception , must lactate must negative serum pregnancy test Screening negative urine pregnancy test result within 24 hour prior receive study drug . The site investigator must ensure female subject pregnant prior receive first dose drug ; Endoscopic evidence inflammation , ulceration , erosion , petechia , active bleeding esophagus , stomach , pyloric channel , duodenum baseline/ randomization ( Day 1 ) endoscopy ( Mucosal Grading Scale score &gt; 0 ) ; Active GI disease ( e.g . inflammatory bowel disease ) , history gastroduodenal ulcer bleed , history gastric duodenal surgery ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>